Brickell Biotech to Host Key Opinion Leader Webinar on DYRK1A and its Role in Autoimmunity

BOULDER, Colo., Sept. 17, 2021 (GLOBE NEWSWIRE) — Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases, today announced that it is scheduled to host a key opinion leader (KOL) webinar on DYRK1A (Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A), which is believed to play a key role in autoimmune and inflammatory diseases, on Friday, September 24, 2021 at 10:00 a.m. EDT.
The webinar will feature a presentation by KOL Bernard Khor, M.D., Ph.D., Benaroya Research …

Read the source article at CentralCharts
2021-09-17 16:00:00